P
Paolo Nuciforo
Researcher at Hebron University
Publications - 223
Citations - 12622
Paolo Nuciforo is an academic researcher from Hebron University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 48, co-authored 186 publications receiving 9779 citations. Previous affiliations of Paolo Nuciforo include Autonomous University of Barcelona & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Raffaella Di Micco,Marzia Fumagalli,Angelo Cicalese,Sara Piccinin,Patrizia Gasparini,Chiara Luise,Catherine Schurra,Massimiliano Garrè,Paolo Nuciforo,Aaron Bensimon,Roberta Maestro,Pier Giuseppe Pelicci,Fabrizio d'Adda di Fagagna +12 more
TL;DR: It is shown that senescence, triggered by the expression of an activated oncogene (H-RasV12) in normal human cells, is a consequence of the activation of a robust DDR, and proposed that OIS results from the enforcement of a DDR triggered by oncogen-induced DNA hyper-replication.
Journal ArticleDOI
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Susan Bullman,Susan Bullman,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Ewa Sicinska,Thomas E. Clancy,Xiaoyang Zhang,Xiaoyang Zhang,Diana Cai,Diana Cai,Donna Neuberg,Katherine H. Huang,Fatima Guevara,Timothy Nelson,Otari Chipashvili,Timothy Hagan,Mark Walker,Aruna Ramachandran,Aruna Ramachandran,Begoña Diosdado,Begoña Diosdado,Garazi Serna,Nuria Mulet,Stefania Landolfi,Santiago Ramón y Cajal,Roberta Fasani,Andrew J. Aguirre,Andrew J. Aguirre,Andrew J. Aguirre,Kimmie Ng,Elena Elez,Shuji Ogino,Shuji Ogino,Josep Tabernero,Charles S. Fuchs,William C. Hahn,William C. Hahn,William C. Hahn,Paolo Nuciforo,Matthew Meyerson,Matthew Meyerson,Matthew Meyerson +41 more
TL;DR: Col colonization of human colorectal cancers with Fusobacterium and its associated microbiome—including Bacteroides, Selenomonas, and Prevotella species—is maintained in distal metastases, demonstrating microbiome stability between paired primary and metastatic tumors.
Journal ArticleDOI
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Suzanne Carreira,Jane C. Goodall,Laurence Denat,Mercedes Rodríguez,Paolo Nuciforo,Keith S. Hoek,Alessandro Testori,Lionel Larue,Colin R. Goding +8 more
TL;DR: In melanomas invasiveness can be regulated epigenetically by the microphthalmia-associated transcription factor, Mitf, via regulation of the DIAPH1 gene encoding the diaphanous-related formin Dia1 that promotes actin polymerization and coordinates the actin cytoskeleton and microtubule networks at the cell periphery.
Journal ArticleDOI
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry,Roberto Salgado,Thomas Gevaert,Prudence A. Russell,Prudence A. Russell,Thomas John,Thomas John,Bibhusal Thapa,Michael Christie,Koen Van de Vijver,Monica V. Estrada,Paula I. Gonzalez-Ericsson,Melinda E. Sanders,Benjamin Solomon,Cinzia Solinas,Gert Van den Eynden,Yves Allory,Yves Allory,Matthias Preusser,Johannes A. Hainfellner,Giancarlo Pruneri,Andrea Vingiani,Sandra Demaria,Fraser Symmans,Paolo Nuciforo,Laura Comerma,E. A. Thompson,Sunil R. Lakhani,Sunil R. Lakhani,Seong Rim Kim,Stuart J. Schnitt,Cecile Colpaert,Christos Sotiriou,Stefan J. Scherer,Michail Ignatiadis,Sunil S. Badve,Robert H. Pierce,Giuseppe Viale,Nicolas Sirtaine,Frédérique Penault-Llorca,Tomohagu Sugie,Susan Fineberg,Soonmyung Paik,Ashok Srinivasan,Andrea L. Richardson,Yihong Wang,Yihong Wang,Ewa Chmielik,Jane E. Brock,Douglas B. Johnson,Justin M. Balko,Stephan Wienert,Veerle Bossuyt,Stefan Michiels,Nils Ternès,Nicole Burchardi,Stephen J Luen,Stephen J Luen,Peter Savas,Peter Savas,Frederick Klauschen,Peter H. Watson,Peter H. Watson,Brad H. Nelson,Brad H. Nelson,Carmen Criscitiello,Sandra A O'Toole,Denis Larsimont,Roland de Wind,Giuseppe Curigliano,Fabrice Andre,Magali Lacroix-Triki,Mark van de Vijver,Federico Rojo,Giuseppe Floris,Shahinaz Bedri,Joseph A. Sparano,David L. Rimm,Torsten O. Nielsen,Zuzana Kos,Stephen M. Hewitt,Baljit Singh,Gelareh Farshid,Gelareh Farshid,Sibylle Loibl,Kimberly H. Allison,Nadine Tung,Sylvia Adams,Karen Willard-Gallo,Hugo M. Horlings,Leena Gandhi,Leena Gandhi,Andre L. Moreira,Fred R. Hirsch,Maria Vittoria Dieci,Maria Urbanowicz,Iva Brcic,Konstanty Korski,Fabien Gaire,Hartmut Koeppen,Amy C. Y. Lo,Amy C. Y. Lo,Jennifer M. Giltnane,Marlon Rebelatto,Keith Steele,Jiping Zha,Kenneth Emancipator,Jonathan Juco,Carsten Denkert,Jorge S. Reis-Filho,Sherene Loi,Stephen B. Fox +111 more
TL;DR: Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Journal ArticleDOI
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado,Carsten Denkert,Christine Campbell,Peter Savas,Paolo Nuciforo,Claudia Aura,Evandro de Azambuja,Holger Eidtmann,Catherine E. Ellis,José Baselga,Martine Piccart-Gebhart,Stefan Michiels,Ian Bradbury,Christos Sotiriou,Sherene Loi +14 more
TL;DR: The presence of TILs at diagnosis is an independent, positive, prognostic marker in HER2-positive early breast cancer treated with neoadjuvant anti-HER2 agents and chemotherapy for both pCR and EFS end points.